The protective effects of sucralfate and ranitidine in foals experimentally intoxicated with phenylbutazone.
The effects of sucralfate and ranitidine on the gastrointestinal manifestations of phenylbutazone (PBZ) toxicity in horse foals were determined by complete blood count, serum chemistry profile, and gross and histological necropsy examinations. Twenty-eight, three to four month old Belgian-cross foals were randomly assigned to one of four groups. Phenylbutazone was administered at a dosage of 10 mg/kg of bodyweight (BW) per day, intravenously (IV), in equally divided doses to three of the groups. In addition to PBZ, ranitidine was administered at 2 mg/kg BW, IV, twice daily, to one group of seven foals (PBZ/ranitidine group), and sucralfate was administered at 4 g, orally, twice daily to another group of seven foals (PBZ/sucralfate group). A fourth group received normal saline IV and corn syrup orally, twice daily, as placebos (control group). Treatments were administered for ten days. Clinical signs included oral ulceration (in all PBZ-treated foals) and diarrhea (5/7 and 2/7 foals from the PBZ and PBZ/ranitidine groups, respectively). A reduction in total protein and albumin was greatest in the PBZ group and least in the PBZ/ranitidine and PBZ/sucralfate groups when compared to the control group. The PBZ group lost weight during the treatment period. At necropsy, the PBZ group had the greatest area of oral ulceration compared to the other treatment groups. All foals treated with PBZ had gastric ulcers; however, the PBZ group had the most severe gastric epithelial necrosis compared to the other three treatment groups. Duodenal villous atrophy, epithelial necrosis and mucosal inflammation, and a reduction in epithelial mitotic figures were seen in all PBZ-treated foals.(ABSTRACT TRUNCATED AT 250 WORDS)
Geor
R J
RJ
Department of Veterinary Internal Medicine, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon.
Petrie
L
L
Papich
M G
MG
Rousseaux
C
C
D000818:Animals; D000831:Animals, Newborn; D001774:Blood Chemical Analysis / Q000662:veterinary; D004066:Digestive System Diseases / Q000139:chemically induced / Q000517:prevention & control / Q000662:veterinary*; D004386:Duodenum / Q000473:pathology; D006403:Hematologic Tests / Q000662:veterinary; D006734:Horse Diseases / Q000139:chemically induced* / Q000517:prevention & control; D006736:Horses; D009059:Mouth Diseases / Q000139:chemically induced / Q000517:prevention & control / Q000662:veterinary; D009336:Necrosis; D010653:Phenylbutazone / Q000633:toxicity*; D011899:Ranitidine / Q000627:therapeutic use*; D013270:Stomach / Q000473:pathology; D013272:Stomach Diseases / Q000139:chemically induced / Q000517:prevention & control / Q000662:veterinary; D013392:Sucralfate / Q000627:therapeutic use*
D013392:Sucralfate; D011899:Ranitidine; D010653:Phenylbutazone